The emerging role of microRNAs in drug responses

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 695-702

  Zhang, Wei ^a   Dolan, M Eileen ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Drug response; gene expression; gene regulation; microRNA; miRNA; pharmacogene; pharmacogenomic

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; INSULIN; INTERFERON; LITHIUM; MICRORNA; PACLITAXEL; SORAFENIB; TAMOXIFEN; TETRAZOLIUM; UNTRANSLATED RNA;

ACUTE LYMPHOCYTIC LEUKEMIA; BILE DUCT CARCINOMA; BIPOLAR DISORDER; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; DOWN REGULATION; DRUG RESPONSE; GENE CONTROL; GENE EXPRESSION; GENOME; HEART INFARCTION; HUMAN; LIVER CANCER; LUNG CANCER; METAZOON; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CANCER; PHARMACOGENOMICS; PHENOTYPE; REVIEW; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; PHARMACOGENETICS; TREATMENT OUTCOME;

METAZOA;

EID: 79952809713     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med (2009) 360(8):790-800.
2. Nannini M, Pantaleo MA, Maleddu A, Astolf A, Formica S, Biasco G: Gene expression profling in colorectal cancer using microarray technologies: Results and perspectives. Cancer Treat Rev (2009) 35(3):201-209.
3. Bacher U, Kohlmann A, Haferlach T: Perspectives of gene expression profling for diagnosis and therapy in haematological malignancies. Brief Funct Genomic Proteomic (2009) 8(3):184-193.
4. Seo D, Ginsburg GS, Goldschmidt-Clermont PJ: Gene expression analysis of cardiovascular diseases: Novel insights into biology and clinical applications. J Am Coll Cardiol (2006) 48(2):227-235. (Pubitemid 44026658) (Pubitemid 44026658)
5. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH: Disease-specifc alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley neuropathology consortium. Mol Psychiatry (2000) 5(2):142-149. (Pubitemid 30229428) (Pubitemid 30229428)
6. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI: Gene expression profling in non-small cell lung cancer: From molecular mechanisms to clinical application. Clin Cancer Res (2004) 10(10):3237-3248. (Pubitemid 38685427) (Pubitemid 38685427)
7. Dacic S: Molecular profling of lung carcinoma: Identifying clinically useful tumor markers for diagnosis and prognosis. Expert Rev Mol Diagn (2007) 7(1):77-86. (Pubitemid 46115933) (Pubitemid 46115933)
8. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol (2004) 22(14):2790-2799. (Pubitemid 41079896) (Pubitemid 41079896)
9. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M: Mapping complex disease traits with global gene expression. Nat Rev Genet (2009) 10(3):184-194.
10. International HapMap Consortium: The international HapMap project. Nature (2003) 426(6968):789-796.
11. International HapMap Consortium: A haplotype map of the human genome. Nature (2005) 437(7063):1299-1320.
12. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME: Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 61(4):413-429.
13. Zhang W, Dolan ME: Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 15(32):3782-3795
14. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME: A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA (2007) 104(23):9758-9763. (Pubitemid 47175340) (Pubitemid 47175340)
15. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME: Identifcation of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 81(3):427-437. (Pubitemid 47330203) (Pubitemid 47330203)
16. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME: Population-specifc genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2009) 113(10):2145-2153.
17. Cheung VG, Spielman RS: Genetics of human gene expression: Mapping DNA variants that infuence gene expression. Nat Rev Genet (2009) 10(9):595-604.
18. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavare S, Deloukas P et al: Genome-wide associations of gene expression variation in humans. PLoS Genet (2005) 1(6):e78.
19. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS: Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet (2003) 33(3): 422-425. (Pubitemid 36278862) (Pubitemid 36278862)
20. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VG: Genetic analysis of genome-wide variation in human gene expression. Nature (2004) 430(7001):743-747. (Pubitemid 39071339) (Pubitemid 39071339)
21. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C et al: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 315(5813):848-853.
22. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME: Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 82(3):631-640.
23. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG: Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet (2007) 39(2):226-231. (Pubitemid 46184354) (Pubitemid 46184354)
24. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S et al: Population genomics of human gene expression. Nat Genet (2007) 39(10):1217-1224. (Pubitemid 47482691) (Pubitemid 47482691)
25. Idaghdour Y, Storey JD, Jadallah SJ, Gibson G: A genome-wide gene expression signature of environmental geography in leukocytes of moroccan amazighs. PLoS Genet (2008) 4(4):e1000052.
26. Lau NC, Lim LP, Weinstein EG, Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in caenorhabditis elegans. Science (2001) 294(5543):858-862. (Pubitemid 33032104) (Pubitemid 33032104)
27. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 433(7027):769-773. (Pubitemid 40292988) (Pubitemid 40292988)
28. Lee CT, Risom T, Strauss WM: Evolutionary conservation of microrna regulatory circuits: An examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny. DNA Cell Biol (2007) 26(4):209-218. (Pubitemid 46776605) (Pubitemid 46776605)
29. Griffths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 34:D140-D144.
30. Griffths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res (2008) 36: D154-158. (Pubitemid 351149713) (Pubitemid 351149713)
31. Griffths-Jones S: The microRNA registry. Nucleic Acids Res (2004) 32:D109-D111.
32. miRBase-The microRNA database: University of Manchester, Manchester, UK (2010). www.mirbase.org
33. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E et al: Identifcation of hundreds of conserved and nonconserved human microRNAs. Nat Genet (2005) 37(7):766-770. (Pubitemid 41754896) (Pubitemid 41754896)
34. He L, Gregory JH: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 5(7):522-531. (Pubitemid 38868508) (Pubitemid 38868508)
35. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2009) 19(1):92-105.
36. Garzon R, Calin GA, Croce CM: MicroRNAs in cancer. Annu Rev Med (2009) 60(1):167-179.
37. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 111(6):3183-3189.
38. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG et al: Genomic profling of microrna and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 68(15):6162-6170.
39. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol (2010) 11(2):136-146.
40. Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP: MicroRNAs in the pathogenesis of lung cancer. J Thorac Oncol (2009) 4(8):1028-1034.
41. Khoshnaw SM, Green AR, Powe DG, Ellis IO: MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol (2009) 62(5):422-428.
42. Mott JL: MicroRNAs involved in tumor suppressor and oncogene pathways: Implications for hepatobiliary neoplasia. Hepatology (2009) 50(2):630-637.
43. Mishra PJ, Mishra PJ, Banerjee D, Bertino JR: miRSNPs or miR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmaco-genomics. Cell Cycle (2008) 7(7):853-858. (Pubitemid 351573776) (Pubitemid 351573776)
44. Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR: miR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One (2009) 4(12):e8445.
45. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA (2007) 104(33):13513-13518. (Pubitemid 47293976) (Pubitemid 47293976)
46. Mishra PJ, Bertino JR: MicroRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics (2009) 10(3): 399-416.
47. Bertino JR, Banerjee D, Mishra PJ: Pharmacogenomics of microRNA: A miRSNP towards individualized therapy. Pharmacogenomics (2007) 8(12):1625-1627.
48. Duan S, Mi S, Zhang W, Dolan ME: Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol (2009) 6(4):412-425.
49. Gomez A, Ingelman-Sundberg M: Epigenetic and microRNA-dependent control of cytochrome P450 expression: A gap between DNA and protein. Pharmacogenomics (2009) 10(7): 1067-1076.
50. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE: Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther (2009) 8(10): 2959-2968.
51. Krishnamurthy P, Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol (2006) 46(1):381-410. (Pubitemid 43271195) (Pubitemid 43271195)
52. McFadyen MC, Murray GI: Cytochrome P450 1B1: A novel anticancer therapeutic target. Future Oncol (2005) 1(2):259-263.
53. Pan YZ, Gao W, Yu AM: MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos (2009) 37(10):2112-2117.
54. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res (2006) 66(18):9090-9098. (Pubitemid 44521128) (Pubitemid 44521128)
55. Pelkonen O, Rautio A, Raunio H, Pasanen M: CYP2A6: A human coumarin 7-hydroxylase. Toxicology (2000) 144(1-3):139-147. (Pubitemid 30201630) (Pubitemid 30201630)
56. Fernandez-Salguero P, Gonzalez FJ: The CYP2A gene subfamily: Species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics (1995) 5 Spec No(1):S123-128.
57. Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P: Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. Carcinogenesis (2008) 29(12):2394-2399.
58. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL et al: A microRNA expression signature of human solid tumors defnes cancer gene targets. Proc Natl Acad Sci USA (2006) 103(7):2257-2261. (Pubitemid 43271657) (Pubitemid 43271657)
59. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Infuence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 116(3):496-526. (Pubitemid 350116943) (Pubitemid 350116943)
60. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL et al: Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics research network and knowledge base. Pharmacogenomics J (2001) 1(3):167-170. (Pubitemid 33756654) (Pubitemid 33756654)
61. PharmGKB-Pharmacogenetics knowledge base: Stanford University, Palo Alto, CA, USA (2010). www.pharmgkb.org
62. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol (2008) 76(5):582-588.
63. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H: A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis (2008) 29(10):1963-1966.
64. Moffat ID, Boutros PC, Celius T, Linden J, Pohjanvirta R, Okey AB: MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci (2007) 99(2):470-487. (Pubitemid 351753064) (Pubitemid 351753064)
65. Norman KL, Sarnow P: Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J Virol (2010) 84(1):666-670.
66. Gandellini P, Folini M, Zaffaroni N: Emerging role of microRNAs in prostate cancer: Implications for personalized medicine. Discov Med (2010) 9(46):212-218.
67. Du L, Pertsemlidis A: MicroRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev (2010) 29(1):109-122.
68. Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG: MicroRNA, cell cycle, and human breast cancer. Am J Pathol (2010) 176(3):1058-1064.
69. Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B, Xu C, Zhang B, Zhang F, Dong D, Song W et al: MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: A new mechanism for ischaemic cardioprotection. Cardiovasc Res (2009) 84(3):434-441.
70. Zhang C: Novel functions for small RNA molecules. Curr Opin Mol Ther (2009) 11(6):641-651.
71. Hummel R, Hussey DJ, Haier J: MicroRNAs: Predictors and modifers of chemo-and radiotherapy in different tumour types. Eur J Cancer (2010) 46(2):298-311.
72. Zheng T, Wang J, Chen X, Liu L: Role of microRNA in anticancer drug resistance. Int J Cancer (2010) 126(1):2-10.
73. Wang V, Wu W: MicroRNA-based therapeutics for cancer. BioDrugs (2009) 23(1):15-23.
74. Kasinski AL, Slack FJ: Potential microRNA therapies targeting Ras, NFκB and p53 signaling. Curr Opin Mol Ther (2010) 12(2): 147-157.
75. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 284(46):32015-32027.
76. Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF: miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood (2009) 114(19):4169-4178.
77. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M et al: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 15(16):5060-5072.
78. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27kip1. J Biol Chem (2008) 283(44):29897-29903.
79. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J: Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics (2006) 3(5):317-324. (Pubitemid 44701551) (Pubitemid 44701551)
80. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM: MicroRNA-143 reduces viability and increases sensitivity to 5-fuorouracil in HCT116 human colorectal cancer cells. Febs J (2009) 276(22):6689-6700.
81. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 111(3):478-486.
82. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN et al: MicroRNA microarray identifes let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 68(24):10307-10314.
83. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: Ras is regulated by the let-7 microRNA family. Cell (2005) 120(5): 635-647. (Pubitemid 40343076) (Pubitemid 40343076)
84. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res (2007) 67(23):11111-11116. (Pubitemid 350248533) (Pubitemid 350248533)
85. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 130(7):2113-2129. (Pubitemid 43816961) (Pubitemid 43816961)
86. He X, He L, Hannon GJ: The guardian's little helper: MicroRNAs in the p53 tumor suppressor network. Cancer Res (2007) 67(23):11099-11101. (Pubitemid 350248530) (Pubitemid 350248530)
87. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L: Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 8(1):266.
88. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX et al: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 361(15):1437-1447.
89. Chen H, Wang N, Burmeister M, McInnis MG: MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol (2009) 1(1):1-7.
90. Granjon A, Gustin MP, Rieusset J, Lefai E, Meugnier E, Guller I, Cerutti C, Paultre C, Disse E, Rabasa-Lhoret R, Laville M et al: The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2c pathway. Diabetes (2009) 58(11):2555-2564.
91. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ: SCAN: SNP and copy number annotation. Bioinformatics (2009) 26(2):259-262.
92. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM et al: MicroRNA expression profles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 6(5):1483-1491. (Pubitemid 46954015) (Pubitemid 46954015)
93. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 67(6):2456-2468. (Pubitemid 46548930) (Pubitemid 46548930)
94. Cancer Facts & Figures: American Cancer Society, Atlanta, GA, USA (2010). www.cancer.org/research/cancerfactsfgures/index
95. Zhang W, Huang RS, Dolan ME: Integrating epigenomics into pharmacogenomic studies. Pharmgenomics Pers Med (2008) 1(1):7-14.